{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:34:27Z","timestamp":1790091267907,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"DOI":"10.7759\/cureus.90755","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:11:27Z","timestamp":1755879087000},"source":"Crossref","is-referenced-by-count":5,"title":["Suzetrigine as a Novel Non-opioid Analgesic Drug in Pain Management: A Review of Clinical Evidence and Therapeutic Perspectives"],"prefix":"10.7759","author":[{"given":"Maciej","family":"Mach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Giba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milosz","family":"Miedziaszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bryla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Szkutnik-Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001939","article-title":"The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises","volume":"161","author":"Raja SN","year":"2020","unstructured":"Raja SN, Carr DB, Cohen M, et al.. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020, 161:1976-82. 10.1097\/j.pain.0000000000001939","journal-title":"Pain"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.673962","article-title":"Cognition and pain: a review","volume":"12","author":"Khera T","year":"2021","unstructured":"Khera T, Rangasamy V. Cognition and pain: a review. Front Psychol. 2021, 12:673962. 10.3389\/fpsyg.2021.673962","journal-title":"Front Psychol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12282","article-title":"Therapeutic basis of clinical pain modulation","volume":"8","author":"Kirkpatrick DR","year":"2015","unstructured":"Kirkpatrick DR, McEntire DM, Hambsch ZJ, et al.. Therapeutic basis of clinical pain modulation. Clin Transl Sci. 2015, 8:848-56. 10.1111\/cts.12282","journal-title":"Clin Transl Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25184257","article-title":"Biased opioid ligands","volume":"25","author":"Faouzi A","year":"2020","unstructured":"Faouzi A, Varga BR, Majumdar S. Biased opioid ligands. Molecules. 2020, 25:4257. 10.3390\/molecules25184257","journal-title":"Molecules"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of Na(V)1.8 with VX-548 for acute pain","volume":"389","author":"Jones J","year":"2023","unstructured":"Jones J, Correll DJ, Lechner SM, et al.. Selective inhibition of Na(V)1.8 with VX-548 for acute pain. N Engl J Med. 2023, 389:393-405. 10.1056\/NEJMoa2209870","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/17581869.2024.2421749","article-title":"VX-548 in the treatment of acute pain","volume":"14","author":"Hang Kong AY","year":"2024","unstructured":"Hang Kong AY, Tan HS, Habib AS. VX-548 in the treatment of acute pain. Pain Manag. 2024, 14:477-86. 10.1080\/17581869.2024.2421749","journal-title":"Pain Manag"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6446(00)01570-1","article-title":"Voltage-gated sodium channels as therapeutic targets","volume":"5","author":"Clare JJ","year":"2000","unstructured":"Clare JJ, Tate SN, Nobbs M, et al.. Voltage-gated sodium channels as therapeutic targets. Drug Discov Today. 2000, 5:506-20. 10.1016\/s1359-6446(00)01570-1","journal-title":"Drug Discov Today"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective Na(V)1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen JD","year":"2025","unstructured":"Osteen JD, Immani S, Tapley TL, et al.. Pharmacology and mechanism of action of suzetrigine, a potent and selective Na(V)1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther. 2025, 14:655-74. 10.1007\/s40122-024-00697-0","journal-title":"Pain Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1573254","article-title":"Sodium channels as a new target for pain treatment","volume":"16","author":"Chen R","year":"2025","unstructured":"Chen R, Liu Y, Qian L, Yi M, Yin H, Wang S, Xiang B. Sodium channels as a new target for pain treatment. Front Pharmacol. 2025, 16:1573254. 10.3389\/fphar.2025.1573254","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.202513778","article-title":"Sensory neuron sodium channels as pain targets; from cocaine to Journavx (VX-548, suzetrigine)","volume":"157","author":"Wood JN","year":"2025","unstructured":"Wood JN, Yan N, Huang J, et al.. Sensory neuron sodium channels as pain targets; from cocaine to Journavx (VX-548, suzetrigine). J Gen Physiol. 2025, 157:e202513778. 10.1085\/jgp.202513778","journal-title":"J Gen Physiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.124.000944","article-title":"State-dependent inhibition of NaV1.8 channels by VX-150 and VX-548","volume":"106","author":"Vaelli P","year":"2024","unstructured":"Vaelli P, Fujita A, Jo S, Zhang HB, Osorno T, Ma X, Bean BP. State-dependent inhibition of NaV1.8 channels by VX-150 and VX-548. Mol Pharmacol. 2024, 106:298-308. 10.1124\/molpharm.124.000944","journal-title":"Mol Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02118-0","article-title":"Drugs in development to manage acute pain","volume":"85","author":"Oliver B","year":"2025","unstructured":"Oliver B, Devitt C, Park G, Razak A, Liu SM, Bergese SD. Drugs in development to manage acute pain. Drugs. 2025, 85:11-9. 10.1007\/s40265-024-02118-0","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2387","article-title":"Gender difference in the pharmacokinetics and metabolism of VX-548 in rats","volume":"45","author":"Yu G","year":"2024","unstructured":"Yu G, Zhou X. Gender difference in the pharmacokinetics and metabolism of VX-548 in rats. Biopharm Drug Dispos. 2024, 45:107-14. 10.1002\/bdd.2387","journal-title":"Biopharm Drug Dispos"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5907","article-title":"A simple and sensitive ultra-high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of VX-548 in monkey plasma: method validation and application to pharmacokinetic study","volume":"38","author":"Zhang H","year":"2024","unstructured":"Zhang H, Chen Y, Huang J, et al.. A simple and sensitive ultra-high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of VX-548 in monkey plasma: method validation and application to pharmacokinetic study. Biomed Chromatogr. 2024, 38:5907. 10.1002\/bmc.5907","journal-title":"Biomed Chromatogr"},{"key":"ref15","unstructured":"Human Protein Atlas. SCN10A gene page. (2023). Accessed: September 10, 2024: https:\/\/www.proteinatlas.org\/search\/scn10a."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-024-01265-z","article-title":"Emerging medications and strategies in acute pain management: evolving role of novel sodium and calcium channel blockers, peptide-based pharmacologic drugs, and non-medicinal methods","volume":"28","author":"Kaye AD","year":"2024","unstructured":"Kaye AD, Greene DR, Nguyen C, et al.. Emerging medications and strategies in acute pain management: evolving role of novel sodium and calcium channel blockers, peptide-based pharmacologic drugs, and non-medicinal methods. Curr Pain Headache Rep. 2024, 28:853-62. 10.1007\/s11916-024-01265-z","journal-title":"Curr Pain Headache Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11010034","article-title":"Acute pain management pearls: a focused review for the hospital clinician","volume":"11","author":"Hyland SJ","year":"2022","unstructured":"Hyland SJ, Wetshtein AM, Grable SJ, Jackson MP. Acute pain management pearls: a focused review for the hospital clinician. Healthcare (Basel). 2022, 11:34. 10.3390\/healthcare11010034","journal-title":"Healthcare (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S144066","article-title":"Poorly controlled postoperative pain: prevalence, consequences, and prevention","volume":"10","author":"Gan TJ","year":"2017","unstructured":"Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017, 10:2287-98. 10.2147\/JPR.S144066","journal-title":"J Pain Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2020.07.016","article-title":"Predicting the transition to chronic pain 6 months after an emergency department visit for acute pain: a prospective cohort study","volume":"59","author":"Friedman BW","year":"2020","unstructured":"Friedman BW, Abril L, Naeem F, et al.. Predicting the transition to chronic pain 6 months after an emergency department visit for acute pain: a prospective cohort study. J Emerg Med. 2020, 59:805-11. 10.1016\/j.jemermed.2020.07.016","journal-title":"J Emerg Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.13075\/ijomeh.1896.01676","article-title":"Neuropathic pain and chronic pain as an underestimated interdisciplinary problem","volume":"35","author":"Szewczyk AK","year":"2022","unstructured":"Szewczyk AK, Jamroz-Wi\u015bniewska A, Haratym N, Rejdak K. Neuropathic pain and chronic pain as an underestimated interdisciplinary problem. Int J Occup Med Environ Health. 2022, 35:249-64. 10.13075\/ijomeh.1896.01676","journal-title":"Int J Occup Med Environ Health"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1054\/jpai.2002.123652","article-title":"Adverse events associated with postoperative opioid analgesia: a systematic review","volume":"3","author":"Wheeler M","year":"2002","unstructured":"Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain. 2002, 3:159-80. 10.1054\/jpai.2002.123652","journal-title":"J Pain"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2025.01010","article-title":"Suzetrigine: the first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain","volume":"19","author":"Hu S","year":"2025","unstructured":"Hu S, Lyu D, Gao J. Suzetrigine: the first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain. Drug Discov Ther. 2025, 19:80-2. 10.5582\/ddt.2025.01010","journal-title":"Drug Discov Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm8147","article-title":"Reducing opioid use disorder and overdose deaths in the United States: a dynamic modeling analysis","volume":"8","author":"Stringfellow EJ","year":"2022","unstructured":"Stringfellow EJ, Lim TY, Humphreys K, et al.. Reducing opioid use disorder and overdose deaths in the United States: a dynamic modeling analysis. Sci Adv. 2022, 8:eabm8147. 10.1126\/sciadv.abm8147","journal-title":"Sci Adv"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.7.729","article-title":"The effectiveness and value of suzetrigine for moderate to severe acute pain: a summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council","volume":"31","author":"Nikitin D","year":"2025","unstructured":"Nikitin D, Rind DM, McQueen B, et al.. The effectiveness and value of suzetrigine for moderate to severe acute pain: a summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council. J Manag Care Spec Pharm. 2025, 31:729-34. 10.18553\/jmcp.2025.31.7.729","journal-title":"J Manag Care Spec Pharm"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1398409","article-title":"Insights into the voltage-gated sodium channel, Na(V)1.8, and its role in visceral pain perception","volume":"15","author":"Heinle JW","year":"2024","unstructured":"Heinle JW, Dalessio S, Janicki P, Ouyang A, Vrana KE, Ruiz-Velasco V, Coates MD. Insights into the voltage-gated sodium channel, Na(V)1.8, and its role in visceral pain perception. Front Pharmacol. 2024, 15:1398409. 10.3389\/fphar.2024.1398409","journal-title":"Front Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00052.2017","article-title":"The role of voltage-gated sodium channels in pain signaling","volume":"99","author":"Bennett DL","year":"2019","unstructured":"Bennett DL, Clark AJ, Huang J, Waxman SG, Dib-Hajj SD. The role of voltage-gated sodium channels in pain signaling. Physiol Rev. 2019, 99:1079-151. 10.1152\/physrev.00052.2017","journal-title":"Physiol Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2025.07.043","article-title":"Targeting Nav1.8 with the nonopioid antagonist suzetrigine in analgesia: cause for optimism?","volume":"11","author":"Attal N","year":"2025","unstructured":"Attal N, Barrot M. Targeting Nav1.8 with the nonopioid antagonist suzetrigine in analgesia: cause for optimism?. Br J Anaesth. 2025, 11:7-912. 10.1016\/j.bja.2025.07.043","journal-title":"Br J Anaesth"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.21.634079","article-title":"Small molecule-mediated targeted protein degradation of voltage-gated sodium channels involved in pain (Preprint)","volume":"2025","author":"Chamessian A","year":"2025","unstructured":"Chamessian A, Payne M, Gordon I, Zhou M, Gereau R. Small molecule-mediated targeted protein degradation of voltage-gated sodium channels involved in pain (Preprint). bioRxiv. 2025, 2025:4079. 10.1101\/2025.01.21.634079","journal-title":"bioRxiv"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/sja.sja_366_25","article-title":"Suzetrigine (VX-548): bidding goodbye to opioids: the latest oral non-opioid analgesic for acute pain","volume":"19","author":"Chittoria K","year":"2025","unstructured":"Chittoria K, Sharma A, Kothari N, Kumari K. Suzetrigine (VX-548): bidding goodbye to opioids: the latest oral non-opioid analgesic for acute pain. Saudi J Anaesth. 2025, 19:384-6. 10.4103\/sja.sja_366_25","journal-title":"Saudi J Anaesth"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000005460","article-title":"Suzetrigine, a nonopioid NaV 1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials","volume":"142","author":"Bertoch T","year":"2025","unstructured":"Bertoch T, D'Aunno D, McCoun J, et al.. Suzetrigine, a nonopioid NaV 1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials. Anesthesiology. 2025, 142:1085-99. 10.1097\/ALN.0000000000005460","journal-title":"Anesthesiology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid Na(V)1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain","volume":"18","author":"McCoun J","year":"2025","unstructured":"McCoun J, Winkle P, Solanki D, et al.. Suzetrigine, a non-opioid Na(V)1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain. J Pain Res. 2025, 18:1569-76. 10.2147\/JPR.S509144","journal-title":"J Pain Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00029-z","article-title":"Vertex's non-opioid painkiller passes phase III tests","volume":"23","author":"Mullard A","year":"2024","unstructured":"Mullard A. Vertex's non-opioid painkiller passes phase III tests. Nat Rev Drug Discov. 2024, 23:162. 10.1038\/d41573-024-00029-z","journal-title":"Nat Rev Drug Discov"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.58347\/tml.2025.1723a","article-title":"Suzetrigine (Journavx) - a sodium channel blocker for acute pain","volume":"67","author":"The Medical Letter","year":"2025","unstructured":"The Medical Letter. Suzetrigine (Journavx) - a sodium channel blocker for acute pain. Med Lett Drugs Ther. 2025, 67:33-5. 10.58347\/tml.2025.1723a","journal-title":"Med Lett Drugs Ther"},{"key":"ref34","unstructured":"FDA approved drug products. JOURNAVX (suzetrigine) tablets, for oral use. (2025). Accessed: July 25, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219209s000lbl.pdf."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2024.04.005","article-title":"Neuroimaging of opioid effects in humans across conditions of acute administration, chronic pain therapy, and opioid use disorder","volume":"47","author":"Martucci KT","year":"2024","unstructured":"Martucci KT. Neuroimaging of opioid effects in humans across conditions of acute administration, chronic pain therapy, and opioid use disorder. Trends Neurosci. 2024, 47:418-31. 10.1016\/j.tins.2024.04.005","journal-title":"Trends Neurosci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/ddc4030032","article-title":"Suzetrigine: a novel non-opioid analgesic for acute pain management - a review","volume":"4","author":"Jones M","year":"2025","unstructured":"Jones M, Demery A, Al-Horani RA. Suzetrigine: a novel non-opioid analgesic for acute pain management - a review. Drugs Drug Candidates. 2025, 4:30032. 10.3390\/ddc4030032","journal-title":"Drugs Drug Candidates"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S526851","article-title":"Suzetrigine approval breaks a 25-year silence: a new era in non-opioid acute pain management","volume":"18","author":"Sibomana O","year":"2025","unstructured":"Sibomana O, Okereke M, Hakayuwa CM. Suzetrigine approval breaks a 25-year silence: a new era in non-opioid acute pain management. J Pain Res. 2025, 18:2805-8. 10.2147\/JPR.S526851","journal-title":"J Pain Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/399895-suzetrigine-as-a-novel-non-opioid-analgesic-drug-in-pain-management-a-review-of-clinical-evidence-and-therapeutic-perspectives","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:11:28Z","timestamp":1755879088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/399895-suzetrigine-as-a-novel-non-opioid-analgesic-drug-in-pain-management-a-review-of-clinical-evidence-and-therapeutic-perspectives"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.90755","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}